Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls. Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79-139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3-7.9)); and 92 healthy controls. Results NfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10-5and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10-5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis. Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome / G. Disanto, R. Adiutori, R. Dobson, V. Martinelli, G.D. Costa, T. Runia, E. Evdoshenko, E. Thouvenot, M. Trojano, N. Norgren, C. Teunissen, L. Kappos, G. Giovannoni, J. Kuhle, L. Bianchi, J. Topping, J. Bestwick, U. Meier, G. Dalla Costa, N. Lazareva, E. Thouvenot, P. Iaffaldano, V. Direnzo, M. Khademi, F. Piehl, M. Comabella, M. Sombekke, J. Killestein, H. Hegen, S. Rauch, S. D'Alfonso, J. Alvarez-Cermeño, P. Kleinová, D. Horáková, R. Roesler, F. Lauda, S. Llufriu, T. Avsar, U. Uygunoglu, A. Altintas, S. Saip, T. Menge, C. Rajda, R. Bergamaschi, N. Moll, M. Khalil, R. Marignier, I. Dujmovic, H. Larsson, C. Malmestrom, E. Scarpini, C. Fenoglio, S. Wergeland, A. Laroni, V. Annibali, S. Romano, A. Martínez, A. Carra, M. Salvetti, A. Uccelli, Ø. Torkildsen, K. Myhr, D. Galimberti, K. Rejdak, J. Lycke, J. Frederiksen, J. Drulovic, C. Confavreux, D. Brassat, C. Enzinger, S. Fuchs, I. Bosca, J. Pelletier, C. Picard, E. Colombo, D. Franciotta, T. Derfuss, R. Lindberg, Ö. Yaldizli, L. Vécsei, B. Kieseier, H. Hartung, P. Villoslada, A. Siva, A. Saiz, H. Tumani, E. Havrdová, L. Villar, M. Leone, N. Barizzone, F. Deisenhammer, C. Teunissen, X. Montalban, M. Tintoré, T. Olsson, M. Trojano, S. Lehmann, G. Castelnovo, S. Lapin, R. Hintzen, R. Furlan, G. Comi, S. Ramagopalan. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - 87:2(2016), pp. 126-129. [10.1136/jnnp-2014-309690]

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

E. Scarpini;C. Fenoglio;D. Galimberti;G. Comi;
2016

Abstract

Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls. Methods We investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79-139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3-7.9)); and 92 healthy controls. Results NfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p=1.5×10-5and OR=7.03; 95% CI 2.85 to 17.34; p=2.3×10-5, respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR=2.36; 95% CI 1.21 to 4.59; p=0.011), gadolinium-enhancing lesions (OR=2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR=2.54; 95% CI 1.21 to 5.31; p=0.013) at CIS diagnosis. Conclusions If replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.
MULTIPLE SCLEROSIS; Adult; Axons; Biomarkers; Demyelinating Diseases; Disease Progression; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neurofilament Proteins; Predictive Value of Tests; Surgery; Neurology (clinical); Psychiatry and Mental Health
Settore BIO/13 - Biologia Applicata
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
5. Disanto.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 582.81 kB
Formato Adobe PDF
582.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/635519
Citazioni
  • ???jsp.display-item.citation.pmc??? 40
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 88
social impact